introduction: thymosin alpha 1 (Ta1) is a natural occurring peptide hormone that is crucial for the maintenance of the organism homeostasis. It has been chemically synthesized and used in diseases where the immune system is hindered or malfunctioning. areas covered: many clinical trials investigate the Ta1 effects in patients with cancer, infectious diseases and as a vaccine enhancer. the number of diseases that could benefit from Ta1 treatment is increasing. to date, questions remain about the physiological basal levels of Ta1 and the most effective dose and schedule of treatment. evidence is growing that diseases characterized by deregulation of immune and/or inflammatory responses are associated with serum levels of Ta1 significantly lower than those of healthy individuals: to date, B hepatitis, psoriatic arthritis, multiple sclerosis and sepsis. the sputum of cystic fibrosis patients contains lower levels of Ta1 than healthy controls. these data are consistent with the role of Ta1 as a regulator of immunity, tolerance and inflammation. expert opinion: Low serum Ta1 levels are predictive and/or associated with different pathological conditions. In case of Ta1 treatment, it is crucial to know the patient’s baseline serum Ta1 level to establish effective treatment protocols and monitor their effectiveness over time.

Pica, F., Gaziano, R., Casalinuovo, I.a., Moroni, G., Buè, C., Limongi, D., et al. (2018). Serum thymosin alpha 1 levels in normal and pathological conditions. EXPERT OPINION ON BIOLOGICAL THERAPY, 18(sup1), 13-21 [10.1080/14712598.2018.1474197].

Serum thymosin alpha 1 levels in normal and pathological conditions

Pica F.
;
Gaziano R.;Casalinuovo I. A.;Moroni G.;Buè C.;Limongi D.;D’Agostini C.;Perricone R.;Palamara A. T.;Sinibaldi Vallebona;
2018-01-01

Abstract

introduction: thymosin alpha 1 (Ta1) is a natural occurring peptide hormone that is crucial for the maintenance of the organism homeostasis. It has been chemically synthesized and used in diseases where the immune system is hindered or malfunctioning. areas covered: many clinical trials investigate the Ta1 effects in patients with cancer, infectious diseases and as a vaccine enhancer. the number of diseases that could benefit from Ta1 treatment is increasing. to date, questions remain about the physiological basal levels of Ta1 and the most effective dose and schedule of treatment. evidence is growing that diseases characterized by deregulation of immune and/or inflammatory responses are associated with serum levels of Ta1 significantly lower than those of healthy individuals: to date, B hepatitis, psoriatic arthritis, multiple sclerosis and sepsis. the sputum of cystic fibrosis patients contains lower levels of Ta1 than healthy controls. these data are consistent with the role of Ta1 as a regulator of immunity, tolerance and inflammation. expert opinion: Low serum Ta1 levels are predictive and/or associated with different pathological conditions. In case of Ta1 treatment, it is crucial to know the patient’s baseline serum Ta1 level to establish effective treatment protocols and monitor their effectiveness over time.
2018
Pubblicato
Rilevanza internazionale
Review
Esperti anonimi
Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA
Settore MEDS-03/A - Microbiologia e microbiologia clinica
English
cancer; chronic inflammatory autoimmune diseases; immune system; immune-deficiency; infectious diseases; Serum thymosin a 1; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Clinical Biochemistry
https://www.tandfonline.com/loi/iebt20
Pica, F., Gaziano, R., Casalinuovo, I.a., Moroni, G., Buè, C., Limongi, D., et al. (2018). Serum thymosin alpha 1 levels in normal and pathological conditions. EXPERT OPINION ON BIOLOGICAL THERAPY, 18(sup1), 13-21 [10.1080/14712598.2018.1474197].
Pica, F; Gaziano, R; Casalinuovo, Ia; Moroni, G; Buè, C; Limongi, D; D’Agostini, C; Tomino, C; Perricone, R; Palamara, At; Sinibaldi, P; P., G...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Serum thymosin alpha 1_EOBT 2018.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 988.71 kB
Formato Adobe PDF
988.71 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/204346
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 16
social impact